Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

S.W. Lam, S.M. de Groot, A.H. Honkoop, A. Jager, A.J. ten Tije, M.M.E.M. Bos, S.C. Linn, J. Bosch, J.R. Kroep, J.J. Braun, H. van Tinteren, E. Boven

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)3077-3088
JournalEuropean Journal of Cancer
Volume50
Issue number18
DOIs
Publication statusPublished - 2014

Cite this

Lam, S.W. ; de Groot, S.M. ; Honkoop, A.H. ; Jager, A. ; ten Tije, A.J. ; Bos, M.M.E.M. ; Linn, S.C. ; Bosch, J. ; Kroep, J.R. ; Braun, J.J. ; van Tinteren, H. ; Boven, E. / Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial. In: European Journal of Cancer. 2014 ; Vol. 50, No. 18. pp. 3077-3088.
@article{9a7ee3b7a2a34f4b94dc0da857ec6435,
title = "Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial",
author = "S.W. Lam and {de Groot}, S.M. and A.H. Honkoop and A. Jager and {ten Tije}, A.J. and M.M.E.M. Bos and S.C. Linn and J. Bosch and J.R. Kroep and J.J. Braun and {van Tinteren}, H. and E. Boven",
year = "2014",
doi = "10.1016/j.ejca.2014.10.008",
language = "Undefined/Unknown",
volume = "50",
pages = "3077--3088",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Pergamon",
number = "18",

}

Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial. / Lam, S.W.; de Groot, S.M.; Honkoop, A.H.; Jager, A.; ten Tije, A.J.; Bos, M.M.E.M.; Linn, S.C.; Bosch, J.; Kroep, J.R.; Braun, J.J.; van Tinteren, H.; Boven, E.

In: European Journal of Cancer, Vol. 50, No. 18, 2014, p. 3077-3088.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: A multicentre, open-label, randomised phase 2 trial

AU - Lam, S.W.

AU - de Groot, S.M.

AU - Honkoop, A.H.

AU - Jager, A.

AU - ten Tije, A.J.

AU - Bos, M.M.E.M.

AU - Linn, S.C.

AU - Bosch, J.

AU - Kroep, J.R.

AU - Braun, J.J.

AU - van Tinteren, H.

AU - Boven, E.

PY - 2014

Y1 - 2014

U2 - 10.1016/j.ejca.2014.10.008

DO - 10.1016/j.ejca.2014.10.008

M3 - Article

VL - 50

SP - 3077

EP - 3088

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 18

ER -